Since there was no significant difference in hHF between dapagliflozin and empagliflozin in T2D patients with a history of established ASCVD, the selection of SGLT2 inhibitors in this population should be based on other clinical factors. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.